The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy

He, Jian; Wang, Zhan; Wáng, Ying; Zou, Ting; Li, Xiangping; Cao, Lei; Chen, Juan

doi:10.2147/pgpm.s325788

Cited by 4 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…making them one of the most extensively documented functionally significant receptors for CCN4 till date [ 32 , 33 , 37 , 74 , 87 , 91 – 95 ]. In addition, CCN4 polymorphism directly influences the risk of developing tumor [ 96 , 97 ], disease progression [ 98 ], response to chemotherapy toxicity [ 99 ] and CCN4 expression via epigenetic modulation such as DNA methylation [ 100 ].…”

Section: Introductionmentioning

confidence: 99%

An overview of CCN4 (WISP1) role in human diseases

Singh,

Oladipupo

2024

J Transl Med

View full text Add to dashboard Cite

CCN4 (cellular communication network factor 4), a highly conserved, secreted cysteine-rich matricellular protein is emerging as a key player in the development and progression of numerous disease pathologies, including cancer, fibrosis, metabolic and inflammatory disorders. Over the past two decades, extensive research on CCN4 and its family members uncovered their diverse cellular mechanisms and biological functions, including but not limited to cell proliferation, migration, invasion, angiogenesis, wound healing, repair, and apoptosis. Recent studies have demonstrated that aberrant CCN4 expression and/or associated downstream signaling is key to a vast array of pathophysiological etiology, suggesting that CCN4 could be utilized not only as a non-invasive diagnostic or prognostic marker, but also as a promising therapeutic target. The cognate receptor of CCN4 remains elusive till date, which limits understanding of the mechanistic insights on CCN4 driven disease pathologies. However, as therapeutic agents directed against CCN4 begin to make their way into the clinic, that may start to change. Also, the pathophysiological significance of CCN4 remains underexplored, hence further research is needed to shed more light on its disease and/or tissue specific functions to better understand its clinical translational benefit. This review highlights the compelling evidence of overlapping and/or diverse functional and mechanisms regulated by CCN4, in addition to addressing the challenges, study limitations and knowledge gaps on CCN4 biology and its therapeutic potential.

show abstract

Section: Introductionmentioning

confidence: 99%

An overview of CCN4 (WISP1) role in human diseases

Singh,

Oladipupo

2024

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Remarkably, the chemotherapy outcomes differ from individual, which means the genetic polymorphisms may play an important role in the efficacy of chemotherapy treatment [7]. Until now, plentiful genetic polymorphisms are associated with the outcomes of chemotherapy, such as Eukaryotic translation Initiation Factor 3 subunit A (eIF3A), Rac family small GTPase 1 (RAC1), WNT1 Inducible Signaling Pathway protein 1 (WISP1), and so on [8][9][10]. The specific mechanisms are still being discovered on the way.…”

Section: Introductionmentioning

confidence: 99%

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Zou,

Liu,

Qin

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Background: Lung cancer is still the most lethal malignancy in the world, according to the report of Cancer Statistics in 2021. Platinum-based chemotherapy combined with immunotherapy is the first-line treatment in lung cancer patients. However, the 5-year survival rate is always affected by the adverse reactions and drug resistance caused by platinum-based chemotherapy. DNA damage and repair system is one of the important mechanisms that can affect the response to chemotherapy and clinical outcomes in lung cancer patients. Objective: The objective of this study is to find the relationship between the polymorphisms of DNA repair genes with the prognosis of platinum-based chemotherapy in lung cancer patients. Patients and Methods: We performed genotyping in 17 single nucleotide polymorphisms (SNPs) of Excision Repair Cross-Complementation group (ERCC) genes and X-ray Repair Cross-Complementing (XRCC) genes of 345 lung cancer patients via Sequenom MassARRAY. We used Cox proportional hazard models, state, and plink to analyze the associations between SNPs and the prognosis of lung cancer patients. Results: We found that the ERCC5 rs873601 was associated with the overall survival time in lung cancer patients treated with platinum-based chemotherapy (p = 0.031). There were some polymorphisms that were related to the prognosis in specific subgroups of lung cancer. Rs873601 showed a great influence on the prognosis of patients more than 55 years, Small Cell Lung Cancer (SCLC), and smoking patients. Rs2444933 was associated with prognosis in age less than 55 years, SCLC, metastasis, and stage III/IV/ED patients. Rs3740051 played an important role in the prognosis of SCLC and metastasis patients. Rs1869641 was involved in the prognosis of SCLC patients. Rs1051685 was related to the prognosis in non-metastasis patients. Conclusion: The ERCC5 rs873601 (G>A) was a valuable biomarker for predicting the prognosis in lung cancer patients treated with platinum-based chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

“…6,7 Genetic polymorphisms are also an important factor affecting the prognosis of chemotherapy and can explain the interindividual difference. 8,9 Therefore, an understanding of different individual and potential genetic variation that might contribute to more effective therapy effect varies for lung cancer. 10 Platinum is mainly eliminated by the proximal tubules in the kidney, and transporters expressed in the kidney play important roles in the distribution and excretion of platinum.…”

Section: Introductionmentioning

confidence: 99%

The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients

He¹,

Wang²,

Zou³

et al. 2022

PGPM

Self Cite

View full text Add to dashboard Cite

Objective Platinum-based chemotherapy is the first-line treatment of lung cancer. However, different individual and genetic variation effect therapy for lung cancer. The purpose of this study was to evaluate the association between transport genes genetic polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients. Methods A series of 593 patients with treatment of platinum-based chemotherapy were recruited for this study. A total of 21 single-nucleotide polymorphisms in nine transporter genes were selected to investigate their associations with platinum-based chemotherapy prognosis. Results Patients with ABCG2 rs1448784 CC genotype had a significantly shorter PFS than CT or TT genotypes (Additive model: HR = 1.54, 95% CI = 1.02–2.35, P = 0.040). In stratification analysis, SLC22A2 rs316003, SLC2A1 rs4658 were related to PFS and AQP9 rs1867380, SLC2A1 rs3820589, SLC22A2 rs316003 indicated were related to OS of platinum-based chemotherapy prognosis. Conclusion Genetic polymorphisms of rs1448784 in ABCG2 might be potential clinical marker for predicting the prognosis of lung cancer patients treated with platinum-based chemotherapy.

show abstract

The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy

Cited by 4 publications

References 36 publications

An overview of CCN4 (WISP1) role in human diseases

An overview of CCN4 (WISP1) role in human diseases

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients

Contact Info

Product

Resources

About